116 related articles for article (PubMed ID: 9334615)
1. Trends in diagnosis of stage T1a-b prostate cancer.
Fowler JE; Pandey P; Bigler SA; Yee DT; Kolski JM
J Urol; 1997 Nov; 158(5):1849-52. PubMed ID: 9334615
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection in candidates for open prostatectomy.
Fowler JE; Bigler SA; Kolski JM
J Urol; 1998 Dec; 160(6 Pt 1):2107-10. PubMed ID: 9817333
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
6. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers.
Tombal B; De Visccher L; Cosyns JP; Lorge F; Opsomer R; Wese FX; Van Cangh PJ
BJU Int; 1999 Dec; 84(9):1015-20. PubMed ID: 10571626
[TBL] [Abstract][Full Text] [Related]
7. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
Jones JS; Follis HW; Johnson JR
Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.
Monda JM; Barry MJ; Oesterling JE
J Urol; 1994 May; 151(5):1291-5. PubMed ID: 7512660
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
Epstein JI; Walsh PC; Brendler CB
J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
12. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
[TBL] [Abstract][Full Text] [Related]
13. [Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml].
Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Bueno Chomón G; Leal Hernández F; Bielsa Carrillo A; García Burgos J
Actas Urol Esp; 1999 Apr; 23(4):316-22. PubMed ID: 10394651
[TBL] [Abstract][Full Text] [Related]
14. Urinary prostate specific antigen: is the clinical use likely?
Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ
BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451
[TBL] [Abstract][Full Text] [Related]
16. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
17. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
19. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
20. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
